The epidermal growth factor receptor family: biology driving targeted therapeutics.
about
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3Epidermal growth factor signaling in transformed cellsThe potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signallingSerum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal studyInsights from molecular modeling, docking and simulation of imidazole nucleus containing chalcones with EGFR kinase domain for improved binding functionEvidence for intermolecular interactions between the intracellular domains of the arabidopsis receptor-like kinase ACR4, its homologs and the Wox5 transcription factorThe growing story of (ARABIDOPSIS) CRINKLY 4.The Tyrosine Kinase Inhibitor Gefitinib Restricts Mycobacterium tuberculosis Growth through Increased Lysosomal Biogenesis and Modulation of Cytokine Signaling.MMP9 modulates tight junction integrity and cell viability in human airway epithelia.Square Cell Packing in the Drosophila Embryo through Spatiotemporally Regulated EGF Receptor SignalingHEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.Targeting the EGF receptor for ovarian cancer therapy.Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patientsAn ordered EST catalogue and gene expression profiles of cassava (Manihot esculenta) at key growth stages.Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users.Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody TherapyTargeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-AnalysisEGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress.Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular SystemMolecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.De novo transcriptome analysis shows differential expression of genes in salivary glands of edible bird's nest producing swiftletsErbB/EGF signaling and EMT in mammary development and breast cancer.Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205LIN-3/EGF promotes the programmed cell death of specific cells in Caenorhabditis elegans by transcriptional activation of the pro-apoptotic gene egl-1.Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding.Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancerEGFR signaling in breast cancer: bad to the bone.A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.Reorienting the Fab domains of trastuzumab results in potent HER2 activators.PKG II inhibits EGF/EGFR-induced migration of gastric cancer cellsMicroarray and deep sequencing cross-platform analysis of the mirRNome and isomiR variation in response to epidermal growth factor.Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.EGFR-binding peptide: a patent evaluation of WO2014002836.Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy.Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells.mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes
P2860
Q27646596-7F53B3A5-D9FC-417D-A88D-F3F98CB00E1DQ28084034-70B969F0-5402-400D-B193-99D898E2E795Q28087571-D6A8F11F-8635-4CD2-959A-2F8E6224538EQ28397818-12CA7567-BE3C-4565-9F3C-074E68724772Q28468338-75DC59A4-E4F1-47F1-8E41-699C84536CEFQ28543936-7F2313F8-7035-4967-8BAF-611F8337D431Q30388382-7702545F-A14E-4BBF-AA19-18DFBD18EA6BQ30402360-F3699461-A72E-416A-A90E-7B2FD0B7F942Q30487603-2E1C399B-ABCD-4381-AE1E-23ACAC8E1658Q30783287-C7D991E0-2E1C-4216-A3EA-9DB341829A3AQ30843463-475233FD-0E26-4069-9D75-0CCDC2EA0D17Q33570526-AB60EE04-90F6-49A2-B69F-26DB12EE0A2FQ33610361-7685E06A-7B05-4B4A-8EC0-8AE666432AA9Q33624574-7B6008DF-A98B-4912-99BC-152C248D3CF1Q33702017-ABBFC20A-35EB-4CD6-8ED3-F4310A95D05FQ33722268-650B334F-AEB7-4FC4-9407-AFF454897F6FQ33722935-BE05DBB9-358C-4355-818A-94F12D62AE28Q33736664-2976133A-42A3-4996-8D16-D4B7D0565D39Q33754779-8BB50FDA-1410-40A2-B5F1-10F81DCE6943Q33779193-E27545F6-4178-408A-98A3-C93DA14B3B28Q33814199-14F53BCD-2C8F-4BB3-AC6C-EE1DC1B0A89EQ33843578-66124EAA-75A2-40B0-AB1C-6579D7F084AEQ33868610-5F3F67BE-6C12-40D5-80D6-C40F6D05F287Q33927493-7342CD9C-D952-48C3-AEFA-DD6FFC9A03DEQ34049250-909AB0D5-5263-4090-856F-45A3D54C1A9BQ34075043-7BF0E1DE-CC30-4EF2-9A3A-7B11D09779C8Q34089704-05B05FBC-B762-41E1-8123-C1D1F69EC08CQ34128530-F415F152-4E28-42BE-80E6-ED9844A25E6DQ34348232-D8936779-EBA4-465A-819A-00C36D067C84Q34361366-70B3DB03-A80C-4EE7-8E94-9A4474225ADBQ34532338-2832F2E3-6C1D-4284-9DF8-FE8784EF9597Q34684803-2A6539CF-D28A-4DC7-937E-BFB033B9D4EEQ34750470-697B6738-DA16-4ED8-AC3A-D8F68457DBF6Q35031831-BDCAA0CB-C742-42B7-899B-68730A2836BAQ35433987-33924A59-74BC-420A-8664-0B3081DF2ED0Q35847701-2F52C107-3D92-4B91-98E0-13B8F1BB1E45Q35882137-D8AF5859-D3ED-4888-874C-700DE1CA5B62Q35911242-6FDBCE7F-FA4C-4B25-86E3-07873CB0435CQ35921941-0FF2E84A-C59D-4D20-9368-00B1C6B9BA3BQ35935148-DE903F82-9179-4BAA-8586-CAF56E556C9F
P2860
The epidermal growth factor receptor family: biology driving targeted therapeutics.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@ast
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@en
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@nl
type
label
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@ast
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@en
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@nl
prefLabel
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@ast
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@en
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@nl
P2860
P1476
The epidermal growth factor receptor family: biology driving targeted therapeutics.
@en
P2093
M J Wieduwilt
M M Moasser
P2860
P2888
P304
P356
10.1007/S00018-008-7440-8
P577
2008-05-01T00:00:00Z